MassDevice

HeartBeam earns FDA clearance for first-ever cable-free 12-lead ECG for at-home arrhythmia assessment

HeartBeam (Nasdaq:BEAT) announced today that it received FDA 510(k) clearance for its 12-lead electrocardiogram (ECG) ...
EMS1

Calif. county to deploy AI-powered ECG devices

Beginning in February, Kern County will become the first in the state to equip all EMS providers with handheld, AI-enabled 12 ...
Science Daily

New AI tool simplifies heart monitoring: Fewer leads, same accuracy

To diagnose heart conditions including heart attacks and heart rhythm disturbances, clinicians typically rely on 12-lead electrocardiograms (ECGs) -- complex arrangements of electrodes and wires ...
Becker's Hospital Review

1st synthesized 12-lead ECG to launch in 2026

HeartBeam's 1st synthesized 12-lead ECG cleared by FDA, enabling cable-free at-home arrhythmia assessment with launch set for 2026.
TipRanks on MSN

HeartBeam (NASDAQ: BEAT) secures FDA 510(k) clearance for 12-lead ECG synthesis software following successful appeal

Austin, Texas, United States, December 10th, 2025, FinanceWire HeartBeam (NASDAQ: BEAT), a medical technology company focused ...
Business Wire

HeartBeam Successfully Meets Clinical Endpoints in Pivotal Study for its Groundbreaking 12-Lead ECG Synthesis Technology

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam, Inc., (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced ...
Business Wire

HeartBeam Achieves Major Milestone with FDA Submission for its Groundbreaking 12-Lead ECG Synthesis Software

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced it ...